Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Chartomatsidou E, Ntoufa S, Kotta K, Rovida A, Akritidou MA, Belloni D, Ferrero E, Trangas T, Stavroyianni N, Anagnostopoulos A, Rosenquist R, Ghia P, Papakonstantinou N, Stamatopoulos K.
Chartomatsidou E, et al. Among authors: trangas t.
Blood Adv. 2019 Jun 25;3(12):1891-1896. doi: 10.1182/bloodadvances.2018030262.
Blood Adv. 2019.
PMID: 31227476
Free PMC article.